Laboratories - the forgotten stakeholder
"Pathologists and laboratories are often overlooked as key stakeholders by pharma and this factor can have a considerable impact on the uptake of targ...
Maria Fe Paz of Diaceutics considers that laboratories will become key influencers, ultimately emerging as one of the most dominant stakeholder groups in the future personalized medicine space.
From the melting pot of opportunity that personalized medicine represents, we contend that stakeholders who had less market power under the traditional model of ‘one size fits all’ drugs will be able to grab a more central role in the effective diffusion of personalized medicine. This has already been witnessed by the invigorating growth of molecular diagnostics driven by a diagnostic industry seeking to move beyond a ‘low price, high volume’ business model to claim equal value for—and reward from—its contribution towards better clinical and financial outcomes.
However, we suggest that it will be clinical laboratories and not the diagnostic companies that will ultimately emerge as one of the most dominant stakeholder groups in the future of personalized medicine. Here are some of the reasons for this bullish view:
This topic will be explored in much more depth as part of an article, ‘The Importance Of Early Engagement With Laboratories To Ensure Seamless Availability Of Companion Diagnostics In Parallel With Therapy Launches’, that we anticipate will be published later this year in a special issue of the Journal of Personalized Medicine edited by Felix Frueh, entitled ‘Untold Stories about Personalized Medicine: If You Thought Personalized Medicine Is for Others to Worry About, Think Again.’
Stay tuned . . .